<img src="https://ml.globenewswire.com/Resource/Download/3dded277-7953-4418-be63-7d7a3067811d?size=2" nborder="0" align="left" hspace="5" vspace="5" title="BioSyent logo.png" alt="BioSyent Inc."/>MISSISSAUGA, Ontario, Aug. 13, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally. As of the date of this press release, the Company has 11,312,635 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit <a href="http://www.tmxmoney.com/" rel="nofollow" target="_blank" title="www.tmxmoney.com">www.tmxmoney.com</a>. For further information please contact: Mr. René C. Goehrum President and CEO BioSyent Inc. E-Mail: <a href="mailto:investors@biosyent.com" rel="nofollow" target="_blank" title="investors@biosyent.com">investors@biosyent.com</a> Phone: 905-206-0013 Web: <a href="http://www.biosyent.com" rel="nofollow" target="_blank" title="www.biosyent.com">www.biosyent.com</a> This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. <img alt="" src='https://ml.globenewswire.com/media/YmUzZWFkZWItY2RhZC00N2JiLWE2YmYtMmFlMTQyMmExNGI2LTExMDEyMzgtMjAyNi0wOC0xMy1lbg==/tiny/BioSyent-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn